Stemline Therapeutics Inc (NASDAQ:STML)

17.75
Delayed Data
As of Jun 19
 0.00 / 0.00%
Today’s Change
7.30
Today|||52-Week Range
20.55
+13.78%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$588.8M

Company Description

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.

Contact Information

Stemline Therapeutics, Inc.
750 Lexington Avenue
New York New York 10022
P:(646) 502-2310
Investor Relations:

Employees

Shareholders

Other institutional38.24%
Mutual fund holders30.21%
Individual stakeholders10.36%

Top Executives

Ivan BergsteinChairman, President & Chief Executive Officer
Kenneth HobermanChief Operating Officer & Secretary
David G. GioncoChief Accounting Officer & Vice President-Finance